Associate editor: K. InuiPharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions
Introduction
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) inhibit the synthesis of mevalonate, a rate-limiting step in cholesterol biosynthesis, leading to a reduction in the plasma low density lipoprotein (LDL)-cholesterol level. High plasma LDL-cholesterol is a risk factor of cardiovascular diseases and, therefore, cholesterol-lowering drugs are used to prevent them. Some randomized controlled trials have shown that statins have potent cholesterol-lowering effects and reduce the risk of cardiovascular diseases in everyday medical practice (Scandinavian Simvastatin Survival Study Group, 1994, Shepherd et al., 1995, Sacks et al., 1996, Bertolini et al., 1997, The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, 1998). On the other hand, some of statins exhibit a number of adverse effects, such as myopathy or rhabdomyolysis (Staffa et al., 2002, Thompson et al., 2003). Concomitant use of other drugs sometimes increases the risk of severe myotoxicity (Pierce et al., 1990, Pogson et al., 1999). Cerivastatin causes a serious myotoxicity, which has resulted in 31 deaths in the USA (Staffa et al., 2002). Among these patients, 12 were concomitantly taking gemfibrozil, suggesting that combination therapy with these drugs might increase the risk of side effects due to a drug–drug interaction (Staffa et al., 2002). Indeed, the plasma concentration of cerivastatin was reported to be increased by coadministration of gemfibrozil (Backman et al., 2002). Due to this severe side effect, cerivastatin was voluntarily withdrawn from the market in 2001. This review will summarize the mechanism of drug–drug interactions between statins and other drugs, using comparisons of the characteristics of statins, their physicochemical properties, elimination routes, and so on.
Mevastatin, a lead compound of the statins, is a fungal product, initially extracted from Penicillium citrinum (Endo et al., 1976). Lovastatin, simvastatin and pravastatin are also derivatives of fungal products (Alberts et al., 1980, Hoffman et al., 1986, Endo, 1992). Among them, lovastatin and simvastatin possess a lactone ring in their structure and are transformed into the active open acid form in the body while pravastatin is administered as the biologically active open acid form (Fig. 1). On the other hand, fluvastatin is a completely synthetic statin with a very different structure from the statins derived from fungal products (Fig. 1). Fluvastatin is a mevalonolactone derivative with a fluorophenyl-substituted indole ring (Fig. 1). Statins, which reached the market after fluvastatin, also have similar structures with fluorophenyl groups. All of the totally synthetic statins have open acid forms. Depending upon their chemical structures, they have different affinities for HMG-CoA reductase, which determines their pharmacological effects, and different pharmacokinetic properties (i.e. tissue distribution, metabolic stability, enzymes and transporters involved in their metabolism, etc.). Thus, the information on the physicochemical properties of statins is useful to understand their pharmacokinetic properties. Drugs which interact with statins depend upon the pharmacokinetic properties of each of statins.
Recently, some reports on genetic polymorphisms in drug metabolizing enzymes and transporters have been published and interindividual differences in the pharmacokinetics of statins associated with them have been reported (Kirchheiner et al., 2003, Nishizato et al., 2003, Kajinami et al., 2004a, Niemi et al., 2004, Wang et al., 2005). This review also summarizes the information on the interindividual differences in pharmacokinetics of statins associated with these genetic factors.
Section snippets
Direct mechanism on 3-hydroxy-3-methylglutaryl coenzyme A reductase
All statins currently on the market possess a HMG-like moiety (Fig. 1): simvastatin and lovastatin have a lactone ring instead of this moiety and are transformed into the biologically active form with an open acid in the body while other newer statins are administered as the open acid forms. Newer statins with HMG-moieties have a higher affinity for HMG-CoA reductase and exert more potent inhibitory effects (Istvan & Deisenhofer, 2001, McTaggart et al., 2001, Holdgate et al., 2003). Enzyme
The characteristics of statins
Statins have different pharmacokinetic profiles that are associated with their physicochemical properties. Table 3 shows the logD values reflecting the lipophilicity of statins. Simvastatin and lovastatin, which are administered as prodrugs with a lactone ring, have high logD values while other statins with open acid structures are less lipophilic. Among them, the logD of pravastatin is the lowest. Generally, compounds with high logD values can easily cross lipid bilayer membranes by passive
Model analysis of pharmacokinetic alterations of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
In Section 3, some factors affecting the pharmacokinetics of statins were reviewed. In this section, we present some quantitative analyses of the effects of these factors (i.e. the increase or decrease in metabolic or transport rates) based on a physiological model. A physiological model based analysis is useful for the quantitative estimation of the impact of these factors on the plasma concentration or AUC. Here, we have carried out an analysis based on a physiological model as shown in Fig. 9
OATP1B1 inhibitor
Among OATP1B1 inhibitors, there are only a few drugs which may cause a drug–drug interaction with coadministered drugs in clinical situations because of the lower therapeutic concentrations compared with Ki (Shitara et al., 2005). Among them, cyclosporin A (CsA) is one of the drugs which may affect the pharmacokinetics of other drugs by the inhibition of OATP1B1-mediated hepatic uptake. In addition, CsA also affects CYP3A4 and P-gp as well as OATP1B1. CsA affects the plasma concentrations of
OATP1B1
There have already been some reports of pharmacokinetic alterations of statins associated with the genetic polymorphism of OATP1B1 (Nishizato et al., 2003, Iwai et al., 2004, Morimoto et al., 2004, Mwinyi et al., 2004, Niemi et al., 2004, Tachibana-Iimori et al., 2004). Fig. 15 shows the reported genetic polymorphisms of this transporter and Table 13 shows the allelic frequencies of the variants found in the OATP1B1 gene (Tirona et al., 2001, Nozawa et al., 2002, Nishizato et al., 2003, Niemi
Conclusion
In this review, we have described the pharmacokinetic properties and physicochemical features of the statins. In addition, we have performed a model-based analysis and shown how sensitively the pharmacokinetic alterations are caused by a change in the metabolizing enzymes and/or transporters. In the case of combination therapy with statins, their elimination pathways and mechanism, which includes the metabolizing enzyme(s) and transporter(s) involved in their elimination, need to be known in
Acknowledgment
We thank Dr. Hitoshi Sato at Showa University and Dr. Toshiharu Horie at Chiba University for their fruitful advices. We also thank Dr. Hideki Fujino at Kowa Co. Ltd. and Dr. Toshihiko Ikeda at Sankyo Co. Ltd. for their critical reviewing of this manuscript. We are also grateful for Ms. Maiko Kawakami-Takada and Dr. Hiroyuki Kusuhara at the University of Tokyo for performing the uptake studies of statins into rat jejunum everted sacs. All simulation analyses were performed using WinNonlin
References (195)
- et al.
Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus
Am J Cardiol
(1995) - et al.
Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients
Am J Transplant
(2001) - et al.
Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery
J Control Release
(1999) - et al.
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
Atherosclerosis
(1997) - et al.
Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells
Atherosclerosis
(2000) - et al.
Clinically relevant differences between the statins: implications for therapeutic selection
Am J Med
(2001) - et al.
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Pharmacol Ther
(1999) - et al.
Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug–drug interactions
Adv Pharmacol
(1997) - et al.
Use of statins in CNS disorders
J Neurol Sci
(2001) The discovery and development of HMG-CoA reductase inhibitors
J Lipid Res
(1992)
Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro
Toxicol Appl Pharmacol
The effect of rifampin treatment on intestinal expression of human MRP transporters
Am J Pathol
Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase–effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdr1a/b gene disruption on tissue distribution in mice
Drug Metab Pharmacokinet
Differential sensitivity of C2–C12 striated muscle cells to lovastatin and pravastatin
J Mol Cell Cardiol
A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters
J Biol Chem
Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus
Atherosclerosis
Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Pharmacol Ther
Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone
Toxicol Appl Pharmacol
CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia
Am J Cardiol
Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease manegement
Atherosclerosis
Tissue- selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor
Biochim Biophys Acta
The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle
Am J Cardiol
Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent
Proc Natl Acad Sci U S A
A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers
J Clin Pharmacol
Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin
Nephron
Plasma concentrations of active simvastatin acid are increased by gemfibrozil
Clin Pharmacol Ther
Gemfibrozil greatly increases plasma concentrations of cerivastatin
Clin Pharmacol Ther
Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia
Br Med J
A receptor-mediated pathway for cholesterol homeostasis
Science
Rhabdomyolysis due to probable interaction between simvastatin and ritonavir
Am J Health Syst Pharm
Effect of itraconazole on the pharmacokinetics of rosuvastatin
Clin Pharmacol Ther
Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects
Br J Clin Pharmacol
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine
Drug Metab Dispos
Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio
Br J Clin Pharmacol
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine
Clin Pharmacol Ther
Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides
Clin Pharmacol Ther
ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium
J Antibiot (Tokyo)
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047
AIDS
Lovastatin decreases coenzyme Q levels in humans
Proc Natl Acad Sci U S A
Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization
Xenobiotica
Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase
Arzneimittelforschung
Effect of gemfibrozil on the metabolism of pitavastatin—determining the best animal model for human CYP and UGT activities
Drug Metabol Drug Interact
Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors
Xenobiotica
Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese
Br J Clin Pharmacol
Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study
J Clin Pharmacol
Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine
Transplantation
Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin
Ann Pharmacother
Cholesterol metabolism in man
West J Med
Simvastatin–nelfinavir interaction implicated in rhabdomyolysis and death
Clin Infect Dis
Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions
J Pharmacol Exp Ther
Cited by (532)
Some pleiotropic effects of statins on hepatocellular carcinoma cells: Comparative study on atorvastatin, rosuvastatin and simvastatin
2023, Advances in Medical SciencesEffects of statin therapy on glycemic control and insulin resistance: A systematic review and meta-analysis
2023, European Journal of PharmacologysmProdrugs: A repository of small molecule prodrugs
2023, European Journal of Medicinal ChemistryRole of Uptake Transporters OAT4, OATP2A1, and OATP1A2 in Human Placental Bio-disposition of Pravastatin
2022, Journal of Pharmaceutical SciencesFamilial hypercholesterolemia
2022, Cholesterol: From Chemistry and Biophysics to the Clinic